The use of intramuscular injections of Botulinum neurotoxin A (BoNT-A) is common in the treatment of hypertonicity and movement disorders. Although most side effects are mild, systemic effects, manifested by generalized weakness distant from the site of injection, have been reported. Previously reported occurrences are discussed, and 3 new cases of patients, who developed systemic weakness after administration of BoNT-A (Botox), despite having tolerated similar injections on several previous occasions, are presented. A review of the literature and reported cases indicate that risk of developing systemic effects does not seem to be related to dose based on body weight. It may be more likely that risk for systemic effects is related to total injection dose and injection frequency. The results of our 3 patients would indicate that injections of greater than 600 units of Botox with follow-up injections occurring every 3 months may lead to an increased risk. We would recommend careful consideration of reinjection frequency if injections of greater than 600 units of Botox are given. Reduction in systemic side effects may occur if reinjection frequency occurs in intervals of 4 months or greater in these individuals.
A 16 year-old male subject with a history of right middle cerebral artery aneurysm rupture at age 10 years with resultant left hemiparesis was seen for 12 injection visits. During visits 1 to 10, he received injections to muscles in his left upper extremity (UE) and, at times, his left gastroc/soleus, quadriceps, or hamstring every 3 to 4 months. Doses of Botox ranged from 3.9 to 11.0 U/kg. After his 11th injection (640 U; 11.0 U/kg into the left flexor carpi radialis, flexor carpi ulnaris, pronator teres, flexor digitorum superficialis, biceps, brachioradialis, and quadriceps muscles), he had difficulty getting on/off his bus. However, this symptom lasted only 1 month and had fully resolved by the time of his next injection. He had previously tolerated 5 injections ranging from 635 to 640 U (10.6Y11.0U/kg) without side effects. He was reinjected 4 months later with 650 U (11.1 U/kg) into the same muscles. Four weeks after injection, he presented with weakness in both UE's and lower extremity (LE's), dysarthria, and increased falls and gait instability. An EMG/nerve conduction study indicated a 26% decrement on repetitive stimulation. At 12 weeks after injection, he had continued difficulty ascending stairs but was no longer falling and had regained full strength in his UEs. Acetylcholine receptor antibodies were not found.
Case 2
A 21 year-old female subject with a history of leukodystrophy and dystonia involving her ocular muscles and erector spinae was seen for 6 injection visits. She tolerated injections well during visits 1 to 5. Her dosage for visits 1 to 4 is unknown because these injections were performed at another medical center. At the time of her fifth visit, performed in our clinic, she received BoNT-A injections (Botox) in her bilateral erector spinae, latissimus dorsi, orbicularis oculi, and corrugator supercilli muscles (760 U; 12.5 U/kg), which were well tolerated without side effects. During her sixth visit 3 months later, she was treated with 760 U (13.2 U/kg) into her bilateral erector spinae and orbicularis oculi. Two weeks after this injection, she presented with increased gait instability/falling, difficulty arising from a chair, difficulty with climbing stairs, and dysphagia. She had 3 to 4/5 strength in proximal UE and LE muscles, dilated but reactive pupils, normal vital capacity, and negative inspiratory force. Electromyogam demonstrated mild, generalized acute denervation.
Muscle biopsy of her deltoid demonstrated fiber size variation, atrophic angulated fibers, and focal group atrophy consistent with neurogenic atrophy. She required hospitalization and inpatient rehabilitation. Her weakness resolved after 6 weeks, although she did not regain full function and strength for 16 weeks. Four months after this injection, she received an intrathecal baclofen pump to reduce her dystonia. She has since had 8 follow-up visits for injections to her upper trapezius and/or ocular muscles (50Y190 U; 0.5Y3.9 U/kg) without side effects.
Case 3
A 38-year-old female subject with spastic left hemiparesis after right posterior fossa meningioma resection received therapeutic BoNT-A (Botox) injections for spasticity on 2 occasions. Her first treatment was an injection of 700 U (7.7 U/kg) into the left biceps, brachialis, pronator teres, flexor digitorum profundus/superficialis, flexor carpi radialis, flexor carpi ulnaris, gastrocnemius/soleus, tibialis posterior, and hamstring muscles. This procedure was well tolerated without side effects. Three months later, she was reinjected with 700 U (7.7 U/kg) into the left pronator teres, flexor digitorum superficialis, gastrocnemius/ soleus, tibialis posterior, and hamstring muscles. Three weeks later, she presented with generalized weakness. She lost the ability to walk, had orthopnea, had difficulty keeping her eyes open, and experienced recurrent episodes of choking. She also had urinary frequency/incontinence. Neurological examination was notable for dysarthria, hypophonia, nystagmus, right lower facial weakness, right ptosis, bilateral tongue weakness, and palatal weakness. She had mild neck weakness, and her previously strong right had 4/5 strength throughout. She had 1 to 2/5 strength on the left. Urinalysis results indicated that she had a urinary tract infection. Electromyogram showed small, narrow, polyphasic motor unit potentials in the right frontalis, deltoid, and biceps muscles. Recruitment was reduced in the frontalis and biceps muscles and early in the deltoid. The frontalis exhibited increased insertional activity with 1+ fibrillations and positive sharp waves. These changes were consistent with acute/chronic denervation with many small, possibly nascent motor unit potentials suggestive of botulinum toxicity. Six weeks later, she had improved dysphagia and right extremity and neck strength but persistent dysarthria and hypophonia. One year after this episode, she was treated with 600 U of BoNT (5.2 U/kg) into her left UE and LE and, again, reported generalized weakness for several days after the injection that resolved spontaneously. She has continued to be reinjected every 3 months with 500 U into her left UE and LE without side effects.
DISCUSSION
We describe 3 patients who developed widespread, systemic spread of Botox in the setting of therapeutic injections. The remote effects on muscle were confirmed with EMG, indicating a severe, systemic adverse outcome. These individuals varied in age (16Y38 years), sex, and diagnosis. Although they differed in which muscles were injected and dose (650Y760 U; 7.7Y13.2 U/kg), they had all tolerated previous injections of similar doses, making these nearly impossible to predict. The risk for development of severe systemic weakness after therapeutic BoNT-A injections could be related to several factors: total injection dose, injection dose based on body weight (U/kg), frequency of injection visits, and patient age.
To attempt to determine commonalities between our cases and other cases of systemic weakness after therapeutic BoNT-A, we performed a literature review for similar reports. The results of this review are in the Table. Three studies report systemic weakness in de novo patients after an initial injection. Duffey and Brown 14 reported UE and LE weakness in a 34-year-old male subject with idiopathic spastic paraparesis who received LE injections, 12 weeks apart, of 1000 U (11 U/kg) and 600 U of Dysport. Additionally, a 57-year-old female subject (1000 U Dysport) and a 24-year-old male subject (300 U Botox) with spinal cord injury received injections to the detrusor for management of neurogenic bladder. Both were noted to have generalized weakness lasting 3 months after injection. Finally, McMahon 18 described a 6-week period of hypotonia and generalized weakness in a 15-month-old with cerebral palsy who received 100 U of Botox (11.5 U/kg) to his calf musculature.
There are several reports that describe systemic weakness after repeated therapeutic injections with BoNT-A. Two studies have reported generalized muscle weakness and electrophysiological changes in noninjected muscles in 5 female adults with dystonia, multiple sclerosis, and multiple systems atrophy. 10, 11 Four of the 5 reported patients had received many injections (Table) of Dysport (250Y900 U) without previous side effects. Goldstein documented symptoms of mild systemic effects (fatigue, ptosis, diplopia, and dysarthria) in a 13-year-old subject with CP who received 23 U/kg of Botox into LE muscles. 15 Her symptoms resolved in 6 weeks, and she did not have any respiratory compromise. She had no adverse reaction to her first injection of 17 U/kg 6 months prior. Additionally, Howell et al 19 documented respiratory stridor and dysphagia in a 9-year-old boy with CP following each of the 4 injection visits treating LE musculature using 20 to 25 U/kg (400 units) of Botox. Although this child had regular systemic effects after recurring injections, the risk of predictable systemic spread in children who have received repeated injections is not consistent across studies. One study reported contralateral weakness in a 53-year-old woman with poststroke spasticity after a fourth injection of 800 units (11 U/kg) into the affected muscles in her paretic UE and LE. 20 Three previous injections of Botox to her UEs of 700 (9.7 U/kg), 500 (6.9 U/kg), and 600 units (83 U/kg) that were spaced 3 months apart were well tolerated. Finally, LeWitt and Trosch 21 documented bilateral nonfatiguing ptosis in a 41-year-old woman after receiving cervical injections (40Y125 U of Botox). Symptoms developed after each of the 12 injection visits with an onset of 1 to 3 days after injection and lasting for several days. There was no decremental response or abnormalities with repetitive stimulation with EMG, and serum antiacetylcholine receptor antibodies were normal.
When choosing an appropriate injection dose for children and adolescents, the injection dose is often based on a patient_s body weight. 22 The dosages used have increased over time. Pediatric doses of BoNT-A for treatment of spasticity in research studies have ranged from 1 to 16.6 U/kg of body weight (Botox). 23, 24 However, in the late 1990s, dose recommendations ranged from 12 to 16 U/kg of body weight. 25Y27 A more recent study has demonstrated no serious adverse events using doses of 15 to 22 U/kg in children weighing less than 45 kg or in young adults weighing 45 kg or greater who received total doses of 800 to 1200 U. 15 Children typically receive higher doses per kilogram of body weight than adults. As a point of reference, patients treated for dystonia typically receive doses in the range of 1.0 to 3.6 U/kg (70Y250 total units) for a 70 kg adult. 28, 29 As a result, children receive doses that are closer to the LD50 for primates (39 U/kg) 30 and may be at greater risk for developing systemic effects than adults.
Because children receive higher doses per kilogram than adults, many studies have examined the incidence of adverse events in children with CP. Bakheit et al 31 reported a 7% rate of adverse events in a study of 1594 treatments in 758 children. The authors concluded that adverse events were more closely related to the total dose given rather than dose based on body weight. However, a retrospective study by Willis et al 22 found an adverse event rate of 4.2% in 929 encounters involving 261 patients. The adverse events were local and not systemic. The authors found no relationship between adverse events and any of the following: dose per kilogram of body weight, CP type, clinical presentation, ambulation status, or duration of treatment with BoNT-A. Additionally, a recent systematic review of randomized clinical trials examining safety of BoNT-A in children with CP found that studies reported only 35 adverse events in 882 participants (4%). 32 They noted that side effects of respiratory tract infection, bronchitis, pharyngitis, asthma, muscle weakness, urinary incontinence, falls, seizures, fever, and unspecified pain were attributed to the injection, whereas other adverse events, such as fatigue, headache, local infection, diarrhea, gastroenteritis, rash, generalized weakness, and cough, were not. However, the authors noted that adverse events were more frequent in children than in adults with other conditions. Patient age does not seem to be an independent risk factor developing systemic weakness after therapeutic injection. There is a wide age range in the reported cases (9Y67 years) with no clustering around a particular age category.
In our 3 reported cases, risk of developing systemic effects does not seem to be related to dose based on body weight, consistent with the findings of Willis et al. 22 Our 3 patients developed systemic weakness after injections of 11.1, 13.2, and 7.7 U/kg. These doses of Botox based on units per kilogram are similar to the adult case reported by Varghese-Kroll and Elvoic 20 but far less than the 2 pediatric cases reported by Howell et al 19 and Goldstein. 15 It may be more likely that risk for systemic effects is related to total injection dose and injection frequency. The results of our 3 patients would indicate that injections of greater than 600 units of Botox with follow-up injections occurring every 3 months may have led to an increased risk. Distant spread also may be mediated by botulinum toxin entry directly into the vascular system through the capillary field or venous system. Although our standard practice of aspirating for blood before injection likely precludes venous injection, capillary uptake likely does occur in some cases. Alternatively, the volume of fluid used for botulinum toxin reconstitution may influence systemic spread. Capillary uptake is likely greater when using larger doses of toxin and/or larger volumes of fluid for injections. It is difficult to compare our findings with other studies, as other authors often report a range of months for frequency of reinjection. Additionally, in their 5 adult cases, Bakheit et al 10 and Bhatia et al 11 used Dysport (vs Botox), which has a conversion factor of approximately 1:3 (1 unit of Botox = 3 units of Dysport). Although the results of their cases demonstrated that lower doses of Botox (using this conversion factor) may result in systemic effects, the duration between injection visits was shorter, making it difficult
